URB2 as an important marker for glioma prognosis and immunotherapy

Chaoyou Fang; Zeyu Zhang; Yongquan Han; Houshi Xu; Zhengyang Zhu; Yichao Du; Pinpin Hou; Ling Yuan; Anwen Shao; Anke Zhang; Meiqing Lou

doi:10.3389/fphar.2023.1113182

URB2 as an important marker for glioma prognosis and immunotherapy

Front Pharmacol. 2023 Mar 24:14:1113182. doi: 10.3389/fphar.2023.1113182. eCollection 2023.

Authors

Chaoyou Fang¹, Zeyu Zhang², Yongquan Han³, Houshi Xu¹, Zhengyang Zhu¹, Yichao Du¹, Pinpin Hou⁴, Ling Yuan¹, Anwen Shao^{5

6}, Anke Zhang^{5

6}, Meiqing Lou¹

Affiliations

¹ Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
³ Department of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
⁴ Central Laboratory, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
⁵ Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China.
⁶ Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, China.

Abstract

Introduction: Glioma is the most common primary brain tumor and primary malignant tumor of the brain in clinical practice. Conventional treatment has not significantly altered the prognosis of patients with glioma. As research into immunotherapy continues, glioma immunotherapy has shown great potential. Methods: The clinical data were acquired from the Chinese Glioma Genome Atlas (CGGA) database and validated by the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) dataset, Clinical Proteomic Tumor Analysis Consortium (CPTAP) database, and Western blot (WB) analysis. By Cox regression analyses, we examined the association between different variables and overall survival (OS) and its potential as an independent prognostic factor. By constructing a nomogram that incorporates both clinicopathological variables and the expression of URB2, we provide a model for the prediction of prognosis. Moreover, we explored the relationship between immunity and URB2 and elucidated its underlying mechanism of action. Results: Our study shows that URB2 likely plays an oncogenic role in glioma and confirms that URB2 is a prognostic independent risk factor for glioma. Furthermore, we revealed a close relationship between immunity and URB2, which suggests a new approach for the immunotherapy of glioma. Conclusion: URB2 can be used for prognosis prediction and immunotherapy of glioma.

Keywords: URB2; glioma; immunity; immunotherapy; prognosis.

Grants and funding

This work was supported by the Natural science foundation of Shanghai (18ZR1430400) and the Zhejiang Provincial Natural Science Foundation of China (LY22H090020).